Type 2 inflammatory biomarkers in asthma and COPD: what we think we know

Clinicians are risk-stratifying asthma and COPD exacerbations based on type 2 inflammatory biomarkers. Measurement of blood eosinophils and FENO have demonstrated promising results in identifying patients who would benefit from oral corticosteroids.